NASDAQ:AMGNAmgen Competitors & Alternatives

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Dividends

Gilead Sciences pays an annual dividend of $2.72 per share and has a dividend yield of 3.6%. Amgen pays an annual dividend of $6.40 per share and has a dividend yield of 2.6%. Gilead Sciences pays out 44.3% of its earnings in the form of a dividend. Amgen pays out 43.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has increased its dividend for 4 consecutive years and Amgen has increased its dividend for 9 consecutive years.

Profitability

This table compares Gilead Sciences and Amgen's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Gilead Sciences and Amgen's revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Gilead Sciences and Amgen, as reported by MarketBeat.com.

Gilead Sciences presently has a consensus price target of $79.6538, suggesting a potential upside of 4.37%. Amgen has a consensus price target of $246.08, suggesting a potential downside of 1.19%. Given Gilead Sciences' higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Amgen.

Institutional & Insider Ownership

78.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 75.7% of Amgen shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Gilead Sciences has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Summary

Amgen beats Gilead Sciences on 13 of the 17 factors compared between the two stocks.

Celgene (NASDAQ:CELG) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and price targets for Celgene and Amgen, as reported by MarketBeat.com.

Celgene presently has a consensus price target of $105.60, suggesting a potential downside of 2.44%. Amgen has a consensus price target of $246.08, suggesting a potential downside of 1.19%. Given Amgen's stronger consensus rating and higher possible upside, analysts clearly believe Amgen is more favorable than Celgene.

Insider and Institutional Ownership

71.7% of Celgene shares are owned by institutional investors. Comparatively, 75.7% of Amgen shares are owned by institutional investors. 0.4% of Celgene shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Celgene and Amgen's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Celgene and Amgen's gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Celgene. Celgene is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Celgene has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.

Summary

Amgen beats Celgene on 10 of the 14 factors compared between the two stocks.

Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Amgen and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Amgen presently has a consensus target price of $246.08, suggesting a potential downside of 1.19%. Vertex Pharmaceuticals has a consensus target price of $285.1154, suggesting a potential downside of 3.17%. Given Amgen's higher possible upside, equities analysts plainly believe Amgen is more favorable than Vertex Pharmaceuticals.

Insider & Institutional Ownership

75.7% of Amgen shares are held by institutional investors. Comparatively, 93.4% of Vertex Pharmaceuticals shares are held by institutional investors. 0.4% of Amgen shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Amgen and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Amgen and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Amgen has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Amgen on 8 of the 14 factors compared between the two stocks.

Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Amgen and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Amgen presently has a consensus target price of $246.08, suggesting a potential downside of 1.19%. Regeneron Pharmaceuticals has a consensus target price of $573.2593, suggesting a potential downside of 7.67%. Given Amgen's higher possible upside, equities analysts plainly believe Amgen is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares Amgen and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Amgen and Regeneron Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Regeneron Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

75.7% of Amgen shares are held by institutional investors. Comparatively, 68.1% of Regeneron Pharmaceuticals shares are held by institutional investors. 0.4% of Amgen shares are held by insiders. Comparatively, 11.3% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility and Risk

Amgen has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

Summary

Amgen beats Regeneron Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current recommendations for Amgen and Biogen, as reported by MarketBeat.

Amgen currently has a consensus target price of $246.08, suggesting a potential downside of 1.19%. Biogen has a consensus target price of $309.6296, suggesting a potential upside of 11.03%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Amgen.

Profitability

This table compares Amgen and Biogen's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Amgen and Biogen's gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

75.7% of Amgen shares are held by institutional investors. Comparatively, 87.3% of Biogen shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Amgen has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Summary

Amgen beats Biogen on 8 of the 14 factors compared between the two stocks.

Amgen (NASDAQ:AMGN) and Seattle Genetics (NASDAQ:SGEN) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current recommendations for Amgen and Seattle Genetics, as reported by MarketBeat.

Amgen currently has a consensus target price of $246.08, suggesting a potential downside of 1.19%. Seattle Genetics has a consensus target price of $148.2778, suggesting a potential downside of 14.95%. Given Amgen's higher possible upside, research analysts plainly believe Amgen is more favorable than Seattle Genetics.

Profitability

This table compares Amgen and Seattle Genetics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Amgen and Seattle Genetics' gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Seattle Genetics. Seattle Genetics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

75.7% of Amgen shares are held by institutional investors. Comparatively, 94.6% of Seattle Genetics shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 31.1% of Seattle Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Amgen has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Seattle Genetics has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Summary

Amgen beats Seattle Genetics on 9 of the 15 factors compared between the two stocks.